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Introduction
Acute lymphoblastic leukemia (ALL) is the most frequently
occurring malignancy in childhood. Currently, the 5-year over-
all survival exceeds 85%.1 Apart from the characteristics of the
leukemia itself, clinical factors that determine treatment
response remain important, such as patients’ compliance and
inter-individual variance of pharmacokinetics.2 The latter is
determined by genetic variation, but also by body composi-
tion. It has been shown that obesity is associated with altered
drug distribution and a subsequent higher mortality rate in
adult cancer.3 Previous studies in pediatric ALL showed contra-
dictory results, i.e. some studies show that weight at diagnosis
does not influence survival, while others suggest that being
underweight or overweight at diagnosis of ALL has an influ-
ence on survival4-14 (Table 1). 
Body composition changes extremely during the treatment
of pediatric ALL due to the use of corticosteroids,15,16 but also
due to other factors such as the catabolic effect of the disease
itself, stress,17 nutritional changes and impaired exercise capac-
ity.11,15,18 This change in body composition may differ between
patients and could affect outcome. So far, only two studies
have addressed the association between therapy-related
change of body composition and outcome.11,14 One study was
conducted in only high-risk pediatric ALL patients14 and the
other was a report from Guatemala.11
It should be noted that previous studies used body mass
index (BMI) as a primary measure and it is generally appreciat-
ed that this index is only a proxy of body composition.19 It has
been shown that dual-energy X-ray absorptiometry (DEXA)
provides a more reliable estimate of body composition by dis-
criminating the relative contribution of bone, fat and lean body
(muscle) mass.20
The aim of this study was to examine the influence of BMI
and its change on treatment outcome in a cohort of Dutch
pediatric ALL patients, including an evaluation of change of
body composition by DEXA in a nested, single-center
cohort. 
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Body mass index and change in body mass index during treatment may influence treatment outcome of pediatric
patients with acute lymphoblastic leukemia. However, previous studies in pediatric acute lymphoblastic leukemia
reported contradictory results. We prospectively collected data on body composition from a cohort of newly diag-
nosed Dutch pediatric patients with acute lymphoblastic leukemia (n=762, age 2-17 years). Patients were treated
from 1997-2004 and the median follow-up was 9 years (range, 0-10). Body mass index at diagnosis was expressed
as age- and gender-matched standard deviation scores and on the basis of these scores the patients were catego-
rized as being underweight, of normal weight or overweight. Multivariate analyses showed that patients who
were underweight (8%) had a higher risk of relapse [hazard ratio: 1.88, 95% confidence interval (1.13-3.13)], but
similar overall survival and event-free survival as patients who had a normal weight or who were overweight.
Patients with loss of body mass index during the first 32 weeks of treatment had a similar risk of relapse and event-
free survival, but decreased overall survival [hazard ratio: 2.10, 95% confidence interval (1.14-3.87)] compared to
patients without a loss of body mass index. In addition, dual X-ray absorptiometry scans were performed in a nest-
ed, single-center cohort. Data from these scans revealed that a loss of body mass consisted mainly of a loss of lean
body mass, while there was a gain in the percentage of fat. In conclusion, being underweight at diagnosis is a risk
factor for relapse, and a decrease in body mass index early during treatment is associated with decreased survival.
In addition, loss of body mass during treatment seems to consist mainly of a loss of lean body mass. This study
was approved by the Medical Ethical Committee in 1996 (trial number NTR460/SNWLK-ALL-9).
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ABSTRACT
Methods
Study population
This study included newly diagnosed pediatric ALL patients,
aged 2-17 years, treated according to the Dutch Childhood
Oncology Group (DCOG) – ALL9 protocol, between January 1997
and November 2004 in seven pediatric oncology centers in the
Netherlands.21 The patients were stratified at diagnosis into non-
high-risk and high-risk treatment groups as previously described.21
For the current study, patients with syndromes or pre-existent
diseases affecting the locomotor system were excluded (Figure 1)
as these influence body composition and/or leukemia outcome.22
Patients were prospectively evaluated from diagnosis to
November 2012 at the central DCOG office. The Medical Ethical
Committee approved the study in 1996. Written informed consent
was obtained according to the Helsinki agreement from all care-
givers and patients aged ≥12 years (trial number NTR460/SNWLK-
ALL-9).
Body composition
Height and weight were measured at diagnosis (T0), after 32
weeks of treatment at the start of ALL maintenance therapy (T1),
at the end of treatment (T2, 109 weeks) and 1 year after the end of
treatment (T3) (Figure 1). 
Height was measured using a Harpenden stadiometer and
weight with a standard clinical scale. Absolute values of BMI were
calculated as weight (m)/height (kg)2.23 A Z-score for age and gen-
der was calculated for weight, height and BMI with reference val-
ues for healthy Dutch peers, and was expressed as a standard devi-
ation score (SDS: Z-score).24-26
On the basis of the BMISDS at diagnosis, patients were divided
into categories: obese and overweight (>1.1 SDS), normal weight (–
1.8SDS to 1.1SDS), and underweight(<–1.8SDS).24,25,27
Change of BMI was measured between diagnosis and 32 weeks
of treatment (T0 to T1), and between diagnosis and cessation of
antileukemic treatment (T0 to T2). Patients were included in the
analysis if BMI was measured at 32 weeks (range, 30-40) or at 109
weeks (range, 104-114). BMI change was analyzed into categories:
BMISDS loss or BMISDS gain. 
To assess the relative contribution of body composition compo-
nents to the change of BMI over time, the percentage (%) fat and
total lean body mass (organs and muscle tissue) were measured by
DEXA (GE Lunar Prodigy, LUNAR Corporation, Madison, WI,
USA). DEXA scans were taken in patients ≥4 years, as reference
values for healthy peers are only available from the age of 4
years.28,29
Statistical analysis
The χ2 test was used to compare frequencies in patients’ vari-
ables between categories of BMI and its changes. The two sample
t-test or analysis of variance (ANOVA) was used to compare nor-
mally distributed, continuous patients’ variables between BMI cat-
egories. 
The primary outcomes of interest were complete remission rate,
event-free survival, cumulative incidence of relapse and overall sur-
vival. The 10-year survival curves for event-free and overall sur-
vival were estimated using the Kaplan-Meier methodology30 and
the two-sided Mantel-Haenszel log-rank test.31 Univariate and
multivariate Cox-regression analyses were used to estimate the
hazard ratio (HR) of BMI categories for event-free and overall sur-
vival.32 To estimate the 10-year cumulative incidence of relapse
curves, a competing risks model was used with death and second
malignancy as competing events.33 All multivariate regression
analyses including BMI at baseline or BMI change were adjusted
for non-high-risk or high-risk group, and BMI at diagnosis as a con-
tinuous variable (only for BMI change). 
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Table 1. Overview of literature assessing the influence of body composition on outcome in pediatric ALL by multivariate analysis.
Year Author Patients Age Measures Outcome
(Reference) (N) (range, years) ↓CRR ↓EFS ↑CIR ↓OS ↑TRM
1994 Viana MB(10) 128 1-15 Weight for height at Dx <-2 SDS <-2 SDS
1994 Reilly JJ(9) 78 1-13 Weight for height at Dx <-0.5 SDS
1998 Weir J(8) 1025 0-15 BMI at Dx No No
NA BMI changeb No No No
2001 Hann I(7) 2090 1-15 BMI at Dx No
2006 Baillargeon J(6) 322 2-18 BMI at Dx No No
2006 Hijiya N(5) 621 1-19 BMI at Dx No No No
2006 Hijiya N(5) NA BMI changec No No No
2007 Butturini AM(4) 4260 and 1733 * 2-20 BMI at Dx ≥ 95th ≥ 95th ≥ 95th No
2011 Gelelete(12) 181 <10 BMI at Dx >1 SDS
2013 Aldhafiri FK(13) 1033 2-15 BMI at Dx No
2013 Antillon(11) 241 1-18 TSFT/MUAC at Dx TSFT and MUAC < 10th 
2013 Antillon(11) 241 TSFT/MUAC changed Decrease
2014 Orgel(14) 2008 1-20 BMI at Dx ≥ 95th ≥ 95th
< 5th < 5th
2014 Orgel(14) 1581 1-20 BMI changea 95th ≥ or < 5th ≥50% time
2014 den Hoed MAH, 762 2-17 BMI at Dx No No ≤-1.8 SDS No No
current study
508 BMI changee No No Decrease
N: number; SDS: standard deviation score; th:  amount of percentile; BMI: body mass index for age and gender (SDS or Z-score); Dx: at diagnosis; CRR: complete remission rate; CIR: cumulative
incidence of relapse; EFS: event-free survival; OS: overall survival; TRM: treatment related mortality (including infection, toxicity,  relapse, death before first complete remission); NA: not available;
“no”:  no association found; empty cells indicate that the outcome was not assessed in the study; TSFT:  triceps skin fold thickness; MUAC:  mid upper arm circumference. *: Verification cohort;
**: Correction of BMI for variables associated with survival outcomes; a: percentage time between end of induction and start of maintenance spent in weight category; b: change after diagnosis;
c: BMI change during entire treatment period; d: BMI change after 6 months of treatment; e:BMI change after 32 weeks of treatment.
Statistical analyses were performed with SPSS 20.0 (SPSS Inc.,
Chicago, IL, USA) and R version 2.15.2 (The R Foundation for
Statistical Computing). P values ≤0.05 (two-sided) were considered
statistically significant.
Additional information on the methods is available in the Online
Supplementary Appendix.
Results
Patients’ demographics
Of the 859 patients registered in the DCOG-ALL9 proto-
col, 762 (463 males, 61%) were eligible for the current study
(Figure 1, Online Supplementary Table S1). The median age at
diagnosis of the patients included was 5.0 years (range, 1.5-
17.3). Complete remission was achieved after induction in
744 (98%) patients. The median follow-up was 9 years
(range, 0.1-10). At 10 years the cumulative incidence of
relapse of the patients included was 17% (SE 1%), the
event-free survival rate was 78% (SE 2%) and the overall
survival rate was 85% (SE 1%); these values are similar to
those previously published for the whole DCOG-ALL-9
group by Veerman et al.21
The nested, single-center subset (n=72) in which DEXA
total body scans were performed was representative of the
total cohort with respect to gender, risk group, white blood
cell count, genetics and extramedullary mass, but the
patients were older than those in the total cohort (median
age 8.5 versus 4.7 years; P<0.001). This was due to the inclu-
sion age for DEXA-scan evaluation, as reference values for
healthy peers are only available from the age of 4 years.28,29
Mean %fat and lean body mass at diagnosis did not differ
according to gender (P=0.429 and P=0.063, respectively),
age at diagnosis (P=0.209 and P=0.131), risk group (P=0.525
and P=0.491), immunophenotype (P=0.583 and P=0.499) or
white blood cell count (P=0.928 and P=0.428) at diagnosis. 
Body mass index at diagnosis
BMISDS data were available for 738 patients (97%) (Figure
1). At diagnosis, 584 patients (79%) had a normal weight,
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Figure 1. CONSORT dia-
gram of the inclusion of
patients in the current
BMI-outcome study. ALL:
acute lymphoblastic
leukemia; DCOG: Dutch
Childhood Oncology
Group; BMI: body mass
index.
59 (8%) were underweight, and 95 (13%) were overweight
or obese. As only 2% of the patients were obese (BMISDS
≥2.3), overweight and obese patients were combined in all
analyses. BMI categories did not differ between patients
who were stratified into the non-high risk or high-risk pro-
tocols (P=0.51). However, younger patients (<10 years)
more often had a normal weight, while older patients were
more likely to be over- or underweight (P=0.016) (Table 2).
Body composition data showed that patients who were
underweight at diagnosis (n=7) were characterized by both
low %fat [mean -1.19 (1.04); P<0.01] and a low lean body
mass [mean -1.75 (0.62), P=0.06] compared to overweight
patients. Inversely, overweight patients (n=10) had both a
high %fat [mean 1.08 (0.85); P<0.01] combined with a rela-
tive high lean body mass [mean -0.33 (0.93); P=0.06]. 
Body mass index at diagnosis and outcome
The complete remission rate did not differ between
patients in different BMISDS categories (Table 3).
Underweight patients were more likely to have experi-
enced a relapse by 10 years of follow up (cumulative inci-
dence of relapse: 31% in underweight patients versus 18%
in normally weighted/overweight patients; P<0.01) (Figure
2, Table 3). In multivariate analysis, after adjustment for risk
group and age, patients who were underweight had an
almost 2-fold higher risk of relapse as compared to those
who were not underweight [cumulative incidence of
relapse: HR 1.88; 95% confidence interval (CI): 1.13-3.13]. 
Being underweight at diagnosis was not associated with
overall or event-free survival (Figure 2, Table 3). There was
no effect modification by age ≥10 years, gender or risk-
group protocol. 
Of the ALL patients who died, all subjects who were
underweight died of leukemia (n=10), whereas patients
who had a normal weight or were overweight died of infec-
tion (n=20), toxicity (n=6), leukemia (n=79) or other causes
(n=3) (Online Supplementary Table S2).
Change in body mass index
A second BMI measurement at 32 weeks of treatment
was available for 508 patients (Figure 1). In 28 cases the
dropout of patients at 32 weeks was caused by relapse,
death, or second malignancy, whereas in 201 patients, BMI
was not documented within the aimed range of 5 weeks
(T1) (Figure 1). The patients with or without a BMI meas-
urement at 32 weeks did not differ with regards to gender,
age at diagnosis, risk group or white blood cell count at
diagnosis. However, patients with a BMI measurement at
32 weeks of therapy were less likely to have T-ALL,
(12.6% versus 36.4%; P<0.01). A third BMI measurement
was available for 435 patients at cessation of treatment
(T2) (Figure 1). The lack of data at cessation of treatment
was caused by relapse, death, or second malignancy in 97
patients, whereas in 206 patients, BMI was not measured
at cessation of treatment in the range of 104-114 weeks
(Figure 1). As compared to patients without a BMI meas-
urement at cessation of treatment, patients with a BMI
measurement had a similar gender distribution, but they
were more often younger than 10 years at diagnosis
(17.2% versus 27.7%; P=0.001); were more likely to have
common ALL (68.1% versus 89.2%; P<0.01); were more
less often at high-risk (23.3% versus 38.2%); and had lower
white blood cell counts [8.1x109/L (range, 0.2-650) versus
13.4x109/L (range, 0.3-926); P=0.001].
BMISDS increased significantly during the first 32 weeks of
therapy [mean 0.85 (SD 0.94); P<0.001]. An increase of one
BMISDS (T1-T0) is equivalent to a gain of 2.27 kg (95% CI
2.01-2.54) or an increase of 1.67 BMI units (95% CI 1.58-
1.75). This increase in BMI in our cohort was shown to be
due not only to an increase in body weight but also to a
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Table 2. Characteristics of patients divided according to BMI category.
BMI groups at diagnosis BMI change*
Underweight Normal weight Overweight Decrease Increase
N (%) N (%) N (%) P N (%) N (%) P
BMI (SDS)
≤ -1.8 - - - NA 2 (4%) 47 (96%) NAa
-1.8 – 1.1 - - - 60 (15%) 333 (85%)
> 1.1 - - - 25 (38%) 41 (62%)
Gender
Male 33 (7%) 355 (79%) 62 (14%) 57 (18%) 254 (82%)
Female 26 (9%) 229 (80%) 33 (11%) 0.503a 30 (15%) 167 (85%) 0.366c
Age at diagnosis 5.0 (1.6-15.6) 5.1 (1.5-17.3) 5.1 (1.6-16.6) 0.310b 4.0 (1.5-17.1) 5.1 (1.5-16.8) 0.035d
(median, range)
Age group (> 10 years)
No 39 (7%) 469 (81%) 69 (12%) 71 (18%) 334 (82%)
Yes 20 (12%) 115 (71%) 26 (17%) 0.016a 16 (16%) 87 (84%) 0.631c
Risk group stratification
Non-high-risk 45 (8%) 404 (79%) 65 (13%) 44 (12%) 310 (88%)
High-risk 14 (6%) 180 (80%) 30 (14%) 0.508a 43 (28%) 111 (72%) <0.001c
Immunophenotype
BCP-ALL 54 (9%) 445 (78%) 74 (13%) 69 (16%) 358 (84%)
T-ALL 3 (2%) 107 (82%) 20 (16%) 0.025a 18 (29%) 45 (71%) 0.016a
White blood-cell count
WBC (x109/L) (median, range) 7.4 (1.2-246.0) 10.2 (0.2-926.0) 8.9 (0.7-590.0) 0.610b 23.2 (1.0-590.0) 9.3 (0.2-650.0) <0.001d
BMI: body mass index; SDS: standard deviation score; BCP: B-cell precursor; WBC: white blood cell count; a: analyses were performed with ANOVA; b: analyses were performed with the Kruskal-
Wallis test: c: analyses were performed using the χ2 test; d: analyses were performed with the Mann-Withney U test; *BMI increase or decrease was measured in the first 32 weeks of treatment. 
delay in growth [T1-T0 mean heightSDS -0.44 (SD 0.47);
P<0.01 and T1-T0 mean weightSDS 0.38 (SD 0.69); P<0.01]
(Online Supplementary Figure S1). 
Patients in the non-high-risk group had a more prominent
increase in BMI during the first 32 weeks of therapy than
had high-risk patients (T1-T0: SDS non-high-risk +0.98 ver-
sus high-risk +0.55; P<0.01), but ultimately there was no
difference in increase in the BMI at the end of therapy
between the high-risk and non-high-risk groups (T2-T0:
non-high-risk: +0.98 SDS versus high-risk: +0.87 SDS;
P=0.36). During the first 32 weeks of therapy 17% (n=87)
of the patients had a decrease in BMISDS; these patients had
a median increase of 0.7 kg in weight (range, -5.50 - 3.50)
and a median loss of -0.58 BMI units (range, -4.20 - 0.33).
Patients who had a decrease in BMISDS (T1-T0) were more
often high-risk patients (P<0.001) and were relatively
younger (P<0.04) (Table 2). Almost all patients who were
underweight at diagnosis (n=49) had an increase in BMI
during the first 32 weeks of therapy (n=47, 96%).
DEXA-scan data from the nested subset showed that this
increase in BMI could be explained by an increase in %fatSDS
[T1-T0: +1.22 (0.90); P<0.01]. Lean body massSDS remained
stable [T1-T0: -0.01 (1.25); P=0.97]. Interestingly, in patients
with a decrease in BMI in the first 32 weeks of treatment
(n=8), %fatSDS still tended to increase, but there was a pre-
dominant loss in lean body massSDS (Online Supplementary
Figure S2). Between discontinuation of therapy and 1 year
thereafter (T3-T2), BMISDS decreased significantly (mean
0.78 to 0.61; P<0.01), but remained higher when compared
to that of healthy peers [mean 0.61 (1.15); P<0.01]. 
Change in body mass index and outcome
The decrease in BMI in the first 32 weeks was associated
with an impaired overall survival [HR: 1.96 (1.10-3.48)].
This association remained significant after adjustment for
baseline BMI, age at diagnosis and risk group [HR: 2.10
(1.14-3.87)] (Figure 3, Table 3). The causes of death in
patients with a decrease in BMI were treatment toxicity
(n=4), second malignancy (n=1) and leukemia (n=11). In
patients who died, the site of the first relapse (P=NA) and
the time between relapse and death (P=0.495) were similar
in patients whose BMI did or did not decrease. Patients
whose BMI decreased seemed to have a higher incidence of
death after relapse than had patients without a decrease in
BMI [n=14 (88%) versus n=38(58%)] (Online Supplementary
Table S3).
A decrease in BMISDS (T1-T0) was not associated with
event-free survival [adjusted HR: 1.51 (0.89-2.58)] or cumu-
lative incidence of relapse [adjusted HRF&G: 1.29 (0.76-2.19)]
(Figure 3, Table 3). A decrease in BMI between diagnosis
and end of therapy (T2-T0) was not associated with event-
free survival, cumulative incidence of relapse or overall sur-
vival (Table 3). There was no effect modification by age ≥10
years, gender or risk-group protocol in any of the analyses. 
During DCOG-ALL9 treatment, the causes of death in
patients with a decrease in BMI were treatment toxicity
(n=1), second malignancy (n=1) and leukemia (n=7) (Online
Supplementary Table S2).
Discussion
The current study shows that being underweight at diag-
nosis is associated with a higher relapse rate, and that a
decrease in BMI during therapy, which seems to be due to
a loss of lean body mass, is associated with decreased over-
all survival in children with ALL. 
So far, contradictory results have been reported on the
impact of BMI at diagnosis on outcome in children with
ALL (Table 1). Studies that showed that baseline BMI was
not associated with outcome included small numbers of
patients in BMI subgroups, or only analyzed the influence
of being overweight on survival.5-8,13 Studies that reported
baseline undernourishment as a determinant of impaired
survival were mostly conducted in developing countries or
had small numbers in the BMI subgroups.9-11 In those series,
patients were, in addition to their disease status and treat-
ment, also coping with additional risk factors for poor out-
come such as malnutrition and poor socioeconomic risk fac-
tors. Our study underscores that the fact of being under-
weight at baseline needs to be taken into account in survival
analyses in pediatric ALL. This confirms the findings of a
recently performed study in a large cohort of high-risk pedi-
atric ALL patients that showed an impaired event-free sur-
vival in patients who were underweight at baseline.14
In our cohort, patients who were underweight at diagno-
sis were more likely to relapse, but this did not eventually
lead to an inferior survival. It is unknown what determines
this influence of baseline weight on relapse occurrence. It
is conceivable that several factors may be involved, includ-
ing impaired immune function, reduced absorption of
treatment medication, and decreased drug-protein
Table 3. Influence of change in BMI on treatment outcomes.
Complete CIR CIR EFS EFS OS OS
Remission Univariate Multivariate Univariate Multivariate Univariate Multivariate
N (%) N (%) HRF&G (95%CI) HRF&G (95%CI) HR (95%CI) HR (95%CI) HR (95%CI) HR (95%CI)
Baseline BMI
BMI  ≤ -1.8 SDS 59 (8%) 58 (98%) 1.94 (1.18 -3.19)* 1.88 (1.13 -3.13)* 1.29 (0.77 -2.15) 1.28 (0.76 -2.15) 1.11 (0.58 -2.13) 1.10 (0.57 -2.10)
BMI  > -1.8 SDS 679 (92%) 652 (96%) 1 1 1 1 1 1
BMI change – 32 weeks
BMI <0 SDS (decrease) 87 (17%) NA 1.29 (0.76 -2.19) 1.45 (0.82 -2.57) 1.37 (0.82 -2.27) 1.51 (0.89 -2.58) 1.96 (1.10 -3.48)* 2.10 (1.14 3.87)*
BMI ≥0 SDS (increase) 421 (83%) NA 1 1 1 1 1 1
BMI change – 109 weeks
BMI <0 SDS (decrease) 75 (17%) NA 0.98 (0.44 -2.19) 1.37 (0.57 -3.08) 0.96 (0.42 -2.15) 1.31 (0.56 -3.03) 0.75 (0.21 -2.70) 0.47 (0.12 -1.78)
BMI ≥0 SDS (increase) 360 (83%) NA 1 1 1 1 1 1
Multivariate analyses were adjusted for (log) age of diagnosis, risk group and baseline BMI SDS. N: number; BMI: body mass index; SDS: standard deviation score; CIR: cumulative incidence of relapse; EFS:
event- free survival; OS: overall survival; HR: hazard ratio; HRF&G: sub-distribution hazard ratio and associated 95% CI for Fine-Gray regression; 95% CI: 95% confidence interval; *P value <0.05. 
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binding,34,35 which are all in general determined by genetic
variation. Patients who were underweight at diagnosis in
our study showed a low lean body mass as well as a low
%fat compared to normal or overweight patients. All these
factors might produce variations in drug pharmacokinet-
ics;34 however, the impact of weight status on pharmacoki-
netics and pharmacodynamics remains under debate in
pediatric oncology as there are conflicting reports.5,36 In the
current study underweight patients had a higher incidence
of relapse, but interestingly, did not experience many
(toxic) events as the event-free survival was similar for
both BMI groups (underweight or not underweight). Our
Weight influences outcome in pediatric ALL
haematologica | 2015; 100(1) 67
Figure 2. Outcomes according to BMI measured at the time of ALL
diagnosis. (A) Kaplan-Meier analysis for event-free survival (EFS), (B)
cumulative incidence of relapse (CIR) and (C) overall survival (OS).
BMI categories: underweight (BMISDS ≤ -1.8, N=59) and other weight
(BMISDS > -1.8, N=679). BMI: body mass index; SDS: standard devia-
tion score. 
Figure 3. Landmark analyses for outcomes according to BMI change
during the first 32 weeks of treatment. (A) Kaplan-Meier estimates
for BMI change during 32 weeks of treatment (T1-T0) for event-free
survival (EFS), (B) cumulative incidence of relapse (CIR) and overall
survival (OS). BMI categories were: BMI decrease (< 0 BMISDS) and
BMI increase (≥ 0 BMISDS). BMI: body mass index; SDS: standard devi-
ation score.
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hypothesis is that the observed lack of serious toxicity in
combination with the higher incidence of relapse in under-
weight patients may be related to minor delays and mild
dosage deviations of treatment which were based on doc-
tors’ choice.37 The underweight group of ALL patients may
have been considered frail by pediatricians, as has been
described in adults.38 That underweight patients received
less therapy is further underscored by the fact that a higher
proportion of such patients could be salvaged, as shown by
the equal overall survival of patients who were under-
weight and those who were not underweight. This may
illustrate that, rather than the aggressive tumor biology, the
cumulative effect of mild therapy adjustments over time
may determine the higher incidence of relapse. This is in
contrast to other reports, in  which it was suggested that
being underweight at diagnosis might also be a reflection
of the biological aggressiveness of the leukemia or the “ill-
ness state”.17
In this study we also analyzed the effect of BMI change
during therapy on treatment outcome in pediatric ALL. One
previous study in 241 ALL patients in South America
revealed that a decrease in body fat, measured by triceps
skin fold thickness and mid upper arm circumference, was
associated with a higher risk of mortality.11 Another study
showed impaired event-free survival when patients were
underweight for ≥50% of the time between diagnosis and
starting maintenance therapy14 (Table 1). We found that a
decrease in BMI during the first 32 weeks of treatment was
associated with increased mortality. To our knowledge this
is the first report that shows that even in patients with a
decrease in BMI, the %fat increased while the muscle mass
substantially decreased. How exactly this decrease affects
survival is unknown. We found that, after a relapse, the sal-
vage of patients with a decrease in BMI was more difficult
than that of patients without a decrease in BMI; i.e. of the
87 patients with a decreased BMI, 14/17 (82%) patients
who suffered a relapse died. In contrast, 38/66 (58%)
patients without a decrease in BMI (n=421) died after hav-
ing a relapse.
Our findings underscore the possible value of supportive
care and lifestyle interventions for patients who are under-
weight at diagnosis and/or have a decrease in BMI in the first
32 weeks of treatment. The results from our nested study
suggest that pediatric ALL patients could benefit from inter-
ventions that enhance lean body mass in addition to com-
monly used interventions, such as nasogastric-tube feeding
including adequate nutrients to avoid a catalytic state. We
also stress the importance of physical exercise programs
early during treatment.39 Furthermore, our findings suggest
that in the future it would be interesting to base chemother-
apy dosing schedules on lean body mass40 rather than on
body surface area to optimize pharmacodynamics in chil-
dren.41 However, in order to design such strategies, it is nec-
essary to unravel the true nature of weight status in individ-
ual patients and confirm the herewith identified effects of
being underweight, loss of weight and change in body com-
position in larger cohorts of ALL patients.
Previous studies suggested that being underweight or
overweight is associated with a compromised outcome in
children with ALL,4,9-12,14 indicating that “extremes” matter.
This has also been shown in pediatric acute myeloid
leukemia.42,43 This U-shaped association seems logical as
both weight status and weight change affect and/or can be
affected by disease severity. Overweight patients may have
a compromised outcome as a result of a deficient immune
response due to higher levels of sex steroids, insulin,
insulin-like growth factor and inflammatory parameters
and have an increased risk of comorbidities related to their
excess weight.15,44 Butturini et al. showed that obesity (>95th
percentile ≈ 30 kg/m2) was an independent predictor of
relapse and mortality in 4260 children with ALL.4 In the cur-
rent study, we were not able to associate obesity with sur-
vival, as only 2% of our population suffered from obesity
(>2.3 SDS ≈ BMI >30 kg/m2). We found no association
between being overweight at baseline and outcome (data
not shown), but the degree of excess weight (>1.1 SDS ≈ BMI
>25 kg/m2) may not have been extreme enough to influence
survival.
We made an attempt to include the development of BMI
after 32 weeks in the analyses by evaluating longitudinal
BMI data. We found that decreases in BMI between the
start, 32 weeks and 109 weeks of treatment were associated
with a decreased overall survival (data not shown). We lost a
very high percentage of patients with BMI decrease in the
first 32 weeks due to death after relapse, which hampered
proper statistical analysis of the effect of BMI change after
32 weeks. We, therefore, appreciate the fact that even larger
cohort studies are necessary to confirm our results. 
We further realized that it is important to adjust for risk
groups in the analyses, as there is a difference in treatment
strategy for patients who are or are not at high risk during
the first 32 weeks of treatment. Multivariate analysis
revealed independent effects of BMI and BMI change on
treatment outcome; even within the risk groups the effects
of BMI and BMI change on outcome were in the same
direction. 
In conclusion, this study confirms that being underweight
at diagnosis is a risk factor for relapse. A decrease in BMI
early during treatment is associated with increased mortal-
ity. This suggests that pediatric ALL patients who are under-
weight at the time of diagnosis, and pediatric ALL patients
with an early decrease in BMI might benefit from cautious-
ness when adjusting treatment, but also from including
exercise interventions in addition to standard diets with
high-quality nutrients during ALL treatment.
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